XTX Topco Ltd Invests $38,000 in InspireMD, Inc. (NYSE:NSPR)

XTX Topco Ltd acquired a new position in shares of InspireMD, Inc. (NYSE:NSPR) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 14,275 shares of the company’s stock, valued at approximately $38,000.

Several other institutional investors also recently modified their holdings of NSPR. Uniting Wealth Partners LLC acquired a new position in InspireMD in the 1st quarter valued at about $27,000. Brown Advisory Inc. acquired a new position in InspireMD in the 1st quarter valued at about $27,000. Renaissance Technologies LLC acquired a new position in InspireMD in the 4th quarter valued at about $27,000. Courier Capital LLC acquired a new position in InspireMD in the 1st quarter valued at about $81,000. Finally, Schonfeld Strategic Advisors LLC grew its stake in InspireMD by 153.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock valued at $79,000 after buying an additional 18,233 shares during the last quarter. 44.78% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other InspireMD news, Director Gary S. Roubin bought 41,322 shares of the firm’s stock in a transaction on Wednesday, July 30th. The shares were purchased at an average price of $2.42 per share, for a total transaction of $99,999.24. Following the transaction, the director directly owned 608,425 shares in the company, valued at approximately $1,472,388.50. This trade represents a 7.29% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Paul Stuka purchased 20,661 shares of the business’s stock in a transaction dated Wednesday, July 30th. The shares were purchased at an average cost of $2.42 per share, with a total value of $49,999.62. Following the acquisition, the director owned 444,195 shares in the company, valued at $1,074,951.90. This trade represents a 4.88% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 103,304 shares of company stock worth $249,996 in the last quarter. Corporate insiders own 34.06% of the company’s stock.

InspireMD Price Performance

Shares of NYSE:NSPR opened at $2.50 on Friday. The company’s 50 day moving average price is $2.42 and its two-hundred day moving average price is $2.60. InspireMD, Inc. has a 12-month low of $1.99 and a 12-month high of $3.80. The firm has a market cap of $104.30 million, a PE ratio of -3.33 and a beta of 0.60.

Analysts Set New Price Targets

A number of brokerages recently commented on NSPR. Piper Sandler decreased their price target on shares of InspireMD from $4.50 to $4.00 and set an “overweight” rating on the stock in a research note on Monday, May 12th. Wall Street Zen began coverage on shares of InspireMD in a research note on Monday, May 5th. They issued a “sell” rating on the stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.